Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA

Nature Biotechnology

Volumn 16, Issue 4, 1998, Pages 364-369

  Nair, Smita K ^a   Boczkowski, David ^a   Morse, Michael ^a   Cumming, R Ian ^a   Lyerly, H Kim ^a   Gilboa, Eli ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antigen presenting cells; Applied immunology; Cancer vaccine

Indexed keywords

CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; COMPLEMENTARY DNA; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; RNA; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNIZATION; CANCER IMMUNOLOGY; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ADENOCARCINOMA; CARCINOEMBRYONIC ANTIGEN; CELL LINE; COLONIC NEOPLASMS; DENDRITIC CELLS; HUMANS; NEOPLASM METASTASIS; RNA; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION; TUMOR CELLS, CULTURED;

MAMMALIA;

EID: 0031960397     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/nbt0498-364     Document Type: Article

References (42)

1. Steinman. R.M. 1981. The dendritic cell system and its role in immunogenicity. Ann. Rsv. Immunol. 9:271-296.
2. Nair, S., Zhou, F., Reddy, R., Huang, L., and Rouse, B.T. 1992. Soluble proteins delivered to dendritic cells via pH-sensitive liposomes induce primary cytotoxic T lymphocyte responses in vitro. J. Exp. Med. 175:609-612.
3. Nair, S., Babu, J.S., Dunham, R.G., Kanda, P., Burke, R.L., and Rouse, B.T. 1993. Induction of primary, antiviral cytotoxic, and proliferative responses with antigens administered via dendritic cells. J. Virol. 67:4062-4069.
4. Rouse, R.J.D., Nair, S.K., Lydy, S.L., Bowen, J.C., and Rouse, B.T. 1994. Induction in vitro of primary cytotoxic T-lymphocyte responses with DNA encoding herpes simplex virus proteins. J. Virol. 68:5685-5689.
5. Porgador, A. and Gilboa, E. 1995. Bone marrow generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J. Exp. Med. 182:255-260.
6. Takahashi, H., Nakagawa, Y., Yokomuro, K., and Berzofsky, J.A. 1993. Induction of CD8* cytotoxic T lymphocytes by immunization with syngeneic irradiated HIV-1 envelope derived peptide-pulsed cells. Int. Immunol. 5:849-857.
7. Zitvogel, L., Mayordomo, J.I., Tjandrawan, T., DeLeo, A.B., Clarke, M.R., Lotze, M.T., and Storkus, W.J. 1996. Therapy of murine tumors with tumor peptidepulsed dendritic cells: dependence on T cells, B7 costimulation. and T helper cell 1-associated cytokines. J. Exp. Med. 183:87-97.
8. Paglia, P., Chiodoni, C., Rodolfo, M., and Colombo, M.P. 1996. Murine dendritic cells loaded in vitro with soluble protein prime CTL against tumor antigen in vivo. J. Exp. Med. 183:317-322.
9. Flamand, V., Sornasse, T., Thielemans, K., Demanet, C., Bakkus, H., Bazin, F. et al. 1994. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur. J. of Immunol. 24:605-610.
10. Porgador, A., Snyder, D., and Gilboa, E. 1996. Induction of antitumor immunity using bone marrow-generated dendritic cells. J. Immunol. 156:2918-2926.
11. Mayordomo, J.I., Zorina, T., Storkus, W.J., Zitvogel, L., Celluzzi, C., Falo, L.D. et al. 1995. Bone marrow-derived dendritic cells pulsed with synthetic tumor peptides elicit protective and therapeutic antitumor immunity. Nat. Med. 1:1297-1302.
12. Hsu, F.J., Benike, C., Fagnoni, F., Liles, T.M., Czerwinski, D., Taidi, B. et al. 1996. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 2:52-58.
13. Ossevoort, M.A., Feltkamp, M.C.W., van Veen, K.J.H., Melief, C.J.M., and Kast. W.M. 1995. Dendritic cells as carriers for a cytotoxic T-lymphocyte epitopebased peptide vaccine in protection against a human papillomavirus type 16-induced tumor. J. Immunotherapy 18:86-94.
14. Nair, S.K., Snyder, D., Rouse, B.T., and Gilboa, E. 1997. Regression of tumors in mice vaccinated with professional antigen presenting cells pulsed with tumor extracts. Int. J. Cancer 70:706-715.
15. Boczkowski, D., Nair, S., Snyder, D., and Gilboa, E. 1996. Dendritic cells pulsed with RNA are potent antigen presenting cells in vitro and in vivo. J. Exp. Med. 184:465-472.
16. Tsang, K.Y., Zaremba, S., Nieroda, C.A., and Schlom, J. 1995. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J. Natl. Cancer Inst. 87:982-989.
17. Celis, E.V., Tsai, S., Crimi, C., DeMars, R., Wentworth, P.A., Chestnut, R.W. et al. 1994. Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc. Natl. Acad. Sci. USA 91:2105-2109.
18. Gagliardi, M.C., Petrillo, G.D., Salemi, S., Boffa, L., Longobardi, M.G., Dellabona, P. et al. 1995. Presentation of peptides by cultured monocytes or activated T cells allows specific priming of human cytotoxic T lymphocytes in vitro. Int. Immunol. 7:1741-1752.
19. Macatonia, S.E., Patterson, S., and Knight, S.C. 1991. Primary proliferative and cytotoxic T-cell responses to HIV induced in vitro by human dendritic cells. Immunology 74:399-406.
20. Mehta-Damani, A., Markowicz, S., and Engleman, E.G. 1994. Generation of antigen-specific CD8* CTLs from naive precursors. J. Immunol. 153:996-1003.
21. Bakker, A.B.H., Marland, G., de Boer, A.J., Huijbens, R.J.F., Danen, E.H.J., Adema, G.J., and Figdor, C.G. 1995. Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro. Cancer Res. 55:5330-5334.
22. Reeves, M., Royal, R.E., Lam, J.S., Rosenberg, S.A., and Hwu, P. 1996. Retroviral transduction of human dendritic cells with a tumor-associated antigen gene. Cancer Res. 56:5672-5677.
23. Wong, C.W., Morse, M., and Nair, S.K. 1998. Induction of primary, human antigen-specific cytotoxic T lymphocytes in vitro using dendritic cells pulsed with peptides. J. Immunotherapy. 21:32-40.
24. Stern, P.L. 1996. Immunity to human papillomavirus-associated cervical neoplasia. Adv. Cancer Res. 69:175-211.
25. Chalfie, M., Tu, Y., Euskirchen, G., Ward, W.W., and Prasher, D.C. 1994. Green fluorescent protein as a marker for gene expression. Science 263:802-805.
26. Felgner, J., Bennett, F., and Feigner, P.L 1993. Cationic lipid-mediated delivery of polynucleotides. Methods: A Companion to Methods in Enzymology 5:67-75.
27. Sallusto, F., Cella, M., Danieli, C., and Lanzavecchia, A. 1995. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J. Exp. Med. 182:389-400.
28. Lanzavecchia, A. 1996. Mechanisms of antigen uptake for presentation. Curr. Opin. Immunol. 8:348-354.
29. Morse, M.A., Zhou, L.-J., Tedder, T.F., Lyerly, K., and Smith, C. 1997. Generation of dendritic cells in vitro from peripheral blood mononuclear cells with GM-CSF, IL-4, and TNFα for use in cancer immunotherapy. Ann. Surgery 226:6-16.
30. Keene, J. and Forman, J. 1982. Helper activity is required for the in vivo generation of cytotoxic T lymphocytes. J. Exp. Med. 155:768-782.
31. von Herrath, M.G., Yokoyama, M., Dockter, J., Oldstone, M.B.A., and Whitton, J.L. 1996. CD4-Deficient mice have reduced levels of memory cytotoxic T lymphocytes after immunization and show diminished resistance to subsequent virus challenge. J. Wol. 70:1072-1079.
32. Bennett, S.R.M., Carbone, F.R., Karamalis, F., Miller, J.F.A.P., and Heath, W.R. 1997. Induction of a CD8* cytotoxic T lymphocyte response by cross-priming requires cognate CD4* T cell help. J. Exp. Med. 186:65-70.
33. Rock, K.L. and K. Clark. 1996. Analysis of the role of MHC class II presentation in the stimulation of cytotoxic T lymphocytes by antigens targeted into the exogenous antigen-MHC class I presentation pathway. J. Immunol. 156:3721-3726.
34. Wu, T.-C., Guarnier, F.G., Staveley-O'Carroll, K.F., Viscidi, R.P., Levitsky, H.I., Hedrick, K.R. et al. 1995. Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc. Natl. Acad. Sci. USA 92:11671-11675.
35. Lin, K.-Y., Guarnier, F.G., Staveley-O'Carroll, K.F., Viscidi, R.P., Levitsky, H.I., Hedrick, K.R. et al. 1996. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 56:21-26.
36. Babu, J.S., Nair, S., Kanda, P, and Rouse, B.T. 1995. Priming for virus-specific CD8* but not CD4* cytotoxic T lymphocytes with synthetic lipopeptide is influenced by acylation units and liposome encapsulation. Vaccine 13:1669-1676.
37. Siliciano, R.F., Lawton, T., Knall, C., Karr, R.W., Berman, P., Gregory, T. et al. 1988. Analysis of host-virus interactions in AIDS with human T cell clones specific for HIV gp120: effect of HIV genomic heterogeneity and a mechanism for CD4* cell depletion. Cell 54:561-575.
38. Kern, D.E., Klarnet, J.P., Jensen, M.C.V., and Greenberg, P.D. 1986. Requirement for recognition of class II molecules and processed tumor antigen for optimal generation of syngeneic tumor-specific class I restricted CTL. J. Immunol. 136:4303-4315.
39. Lechler, R., Aichinger, G., and Lightstone L. 1996. The endogenous pathway of MHC class II antigen presentation. Immunol. Rev. 151:51-79.
40. Salter, R.D., Howell, D.N., and Cresswell, P. 1985. Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids. Immunogenetics 21:235-246.
41. Romani, N., Gruner, S., Brang, D., Kampgen, E., Lenz, A., Trockenbacher, B. et al. 1994. Proliferating dendritic cell progenitors in human blood. J. Exp. Med. 180:83-93.
42. Volgmann, T., Klein-Struckmeier, A., and Mohr, H. 1989. A fluorescence-based assay for quantitation of lymphokine-activated killer cell activity. J. Immunol. Methods 119:45-51.